Latest News & Features
article
Court outlines submission method in the event of CMS failure | Hard-copy format requirements include USB stick and delivery to Luxembourg | Guidelines have “made people nervous” say lawyers | Full details on how to submit. 30 May 2023
Medtech
Medtronic prior art reference does not qualify, says Federal Circuit | Firm was hoping to invalidate five catheter technology patents. 25 May 2023
Big Pharma
Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents. 25 May 2023
Big Pharma
Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children. 23 May 2023
Big Pharma
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider. 23 May 2023
Big Pharma
Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies. 18 May 2023
Big Pharma
The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account. 18 May 2023
Big Pharma
The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments. 18 May 2023
article
The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market. 16 May 2023
article
Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year. 16 May 2023